CEL-SCI Corp. (CVM) Raises Capital to Fund Phase III Trials
CEL-SCI Corp (CVM) recently announced that it raised equity capital to fund further research and clinical trials of some of its drug candidates, including an anti cancer drug and one to treat swine flu. The company sold 4,285,715 shares of common stock at $1.40 per share, yielding gross proceeds of approximately $19 million. Investors who participated in the offering also received warrants to purchase additional shares at $1.50 per share. The warrants expire in two years. CEL-SCI Corp is using the funds to begin a Phase III clinical trial for Multikline, a cancer drug used to treat advanced primary head…